Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 7, 2011, Pages 1195-1200

  Nouso, Kazuhiro ^a   Kobayashi, Yoshiyuki ^a   Nakamura, Shinichiro ^a   Kobayashi, Sayo ^a   Takayama, Hiroki ^a   Toshimori, Junichi ^a   Kuwaki, Kenji ^a   Hagihara, Hiroaki ^a   Onishi, Hideki ^a   Miyake, Yasuhiro ^a   Ikeda, Fusao ^a   Shiraha, Hidenori ^a   Takaki, Akinobu ^a   Iwasaki, Yoshiaki ^a   Kobashi, Haruhiko ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alpha fetoprotein; Fucosylation; Hepatocellular carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; DECARBOXYPROTHROMBIN; INTERFERON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; FEMALE; FUCOSYLATION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; RISK FACTOR; SURVIVAL TIME; TUMOR THROMBUS; TUMOR VOLUME;

EID: 79958824201     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06720.x     Document Type: Article

References (23)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2: 533-43.
2. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer 2007; 43: 979-92.
3. Nouso K, Kobayashi Y, Nakamura S etal. Evolution of prognostic factors in hepatocellular carcinoma in Japan. Aliment. Pharmacol. Ther. 2010; 31: 407-14.
4. Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin. Liver Dis. 2005; 25: 171-80.
5. Varela M, Sala M, Llovet JM, Bruix J. Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2003; 17 (Suppl. 2): 98-102.
6. Toyoda H, Kumada T, Kaneoka Y etal. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J. Hepatol. 2008; 49: 223-32.
7. Kagebayashi C, Yamaguchi I, Akinaga A etal. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal. Biochem. 2009; 388: 306-11.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
9. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J. Gastroenterol. 2006; 12: 828-9.
10. Comunale MA, Wang M, Hafner J etal. Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J. Proteome Res. 2009; 8: 595-602.
11. Wang M, Long RE, Comunale MA etal. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 2009; 18: 1914-21.
12. Yanagidani S, Uozumi N, Ihara Y, Miyoshi E, Yamaguchi N, Taniguchi N. Purification and cDNA cloning of GDP-L-Fuc: N-acetyl-beta-D-glucosaminide:alpha1-6 fucosyltransferase (alpha1-6 FucT) from human gastric cancer MKN45 cells. J. Biochem. 1997; 121: 626-32.
13. Noda K, Miyoshi E, Uozumi N etal. Gene expression of alpha1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alpha-fetoprotein. Hepatology 1998; 28: 944-52.
14. Nakamura S, Nouso K, Sakaguchi K etal. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am. J. Gastroenterol. 2006; 101: 2038-43.
15. Oka H, Saito A, Ito K etal. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J. Gastroenterol. Hepatol. 2001; 16: 1378-83.
16. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995; 22: 802-7.
17. Taketa K, Endo Y, Sekiya C etal. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 1993; 53: 5419-23.
18. Sterling RK, Jeffers L, Gordon F etal. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2009; 7: 104-13.
19. Marrero JA, Feng Z, Wang Y etal. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-18.
20. Ikoma J, Kaito M, Ishihara T etal. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002; 49: 235-8.
21. Kasahara A, Hayashi N, Fusamoto H etal. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig. Dis. Sci. 1993; 38: 2170-6.
22. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82: 1643-8.
23. Tanabe Y, Ohnishi K, Nomura F, Iida S. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma. Am. J. Gastroenterol. 1988; 83: 1386-9.